Tag: MindMed - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Post published:August 25, 2022
Post category:Press Release

Read more about the article MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

Post published:April 14, 2022
Post category:Press Release

Read more about the article MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Post published:April 5, 2022
Post category:Press Release

Read more about the article MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Reports Full Year 2021 Financial Results and Business Highlights

Post published:March 28, 2022
Post category:Press Release

Read more about the article MindMed Announces Transition of CFO

MindMed Announces Transition of CFO

Post published:March 25, 2022
Post category:Press Release

Read more about the article MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

Post published:February 23, 2022
Post category:Press Release

Read more about the article FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Post published:January 25, 2022
Post category:Press Release

Read more about the article MindMed Enrolls First Participant in a Study of its Session Monitoring System

MindMed Enrolls First Participant in a Study of its Session Monitoring System

Post published:January 18, 2022
Post category:Press Release

Read more about the article Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

Post published:January 7, 2022
Post category:Press Release

Read more about the article MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

Post published:January 4, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.